KPV

Description

KPV is a tripeptide (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (α-MSH). While α-MSH is a 13-amino acid peptide with broad systemic effects, researchers identified KPV as the minimal sequence responsible for its anti-inflammatory activity — delivering targeted action without the melanogenic side effects of the full molecule.

Research Profile

KPV works primarily through inhibition of NF-κB signaling — the master inflammatory transcription factor. Studies published in journals including PNAS and the Journal of Biological Chemistry demonstrate its ability to enter cells, accumulate in the nucleus, and directly suppress inflammatory gene transcription. This mechanism operates independently of melanocortin receptors, distinguishing KPV from other α-MSH derivatives.

Key Research Areas

• NF-κB pathway inhibition
• Inflammatory bowel and mucosal inflammation models
• Skin inflammation and wound healing
• Antimicrobial activity (Staphylococcus aureus, Candida albicans)
• Gut barrier integrity and permeability

Specifications

Sequence	Lys-Pro-Val
Molecular Weight	342.43 g/mol
Purity	≥99% (HPLC verified)
Form	Lyophilized powder
Quantity	5mg per vial
Storage	-20°C pre-reconstitution

Related Research Peptides

Researchers investigating inflammation often pair KPV studies with BPC-157 (gut protection) and LL-37 (antimicrobial defense). See our healing peptides guide for a complete overview.

Research Dosage Protocols

KPV (Lys-Pro-Val) research spans both oral and injectable routes. Gut-targeted studies have used encapsulated oral delivery at 1–10mg/kg to evaluate local intestinal anti-inflammatory effects, while systemic studies use subcutaneous injection at 0.1–1mg/kg. A 10mg vial reconstituted in 2mL bacteriostatic water yields 5mg/mL. KPV’s small size (just three amino acids) gives it favorable oral stability compared to larger peptides — studies using nanoparticle encapsulation show effective colonic delivery. Typical experimental windows in IBD models run 2–4 weeks, with endpoints measuring cytokine profiles and histological scores.

Frequently Asked Questions

Does KPV work better via oral or injectable administration for gut research?

For GI-specific research, oral delivery — particularly with encapsulation designed for colonic release — is more relevant because it delivers KPV directly to the intestinal epithelium where MC1R receptors are expressed. Injectable routes distribute KPV systemically, which is appropriate for studying systemic anti-inflammatory effects but less targeted for gut mucosa. Published research from Emory University used orally-delivered nanoparticle-encapsulated KPV in colitis models with strong results. For researchers studying IBD specifically, oral encapsulated delivery mirrors a therapeutic delivery route more closely than subcutaneous injection.

How specific is KPV’s NF-κB inhibition compared to other anti-inflammatory compounds?

KPV inhibits NF-κB activation through MC1R (melanocortin-1 receptor) binding, which triggers downstream cAMP/PKA signaling that suppresses IκB kinase activity — preventing NF-κB nuclear translocation. This mechanism is notably distinct from non-specific anti-inflammatory agents like corticosteroids, which suppress immune function broadly. KPV’s NF-κB inhibition is receptor-mediated and shows tissue selectivity where MC1R is expressed (gut epithelium, skin, immune cells). Research comparing KPV to dexamethasone in intestinal models shows comparable reduction of IL-6, TNF-α, and IL-1β without the metabolic side effects associated with glucocorticoid receptor agonism.

What makes KPV useful specifically for gut-targeted research protocols?

MC1R is highly expressed on intestinal epithelial cells and lamina propria macrophages — two cell populations central to IBD pathology. KPV’s small tripeptide structure survives partial GI transit when appropriately formulated, meaning it can reach the colonic mucosa intact. Published colitis model data shows KPV reduces myeloperoxidase activity (a marker of neutrophil infiltration), decreases pro-inflammatory cytokine expression in colonic tissue, and improves histological damage scores. The fact that it works at the mucosal surface rather than requiring systemic exposure makes it a mechanistically clean tool for intestinal inflammation research.

How does KPV differ from the full alpha-MSH molecule?

Alpha-MSH is a 13-amino acid neuropeptide. KPV represents the C-terminal tripeptide (positions 11–13) of alpha-MSH. Early research identified the C-terminal segment as responsible for alpha-MSH’s anti-inflammatory activity — the N-terminal region drives most of the pigmentation effects through MC1R at different binding dynamics. KPV retains the anti-inflammatory mechanism without the pigmentation stimulation associated with full alpha-MSH. This selectivity is why researchers studying inflammation specifically prefer KPV over the full molecule — it allows investigation of NF-κB and cytokine pathways without confounding melanin synthesis responses.

How stable is KPV, and what are the reconstitution requirements?

KPV is relatively stable compared to larger peptides due to its small size and simple tripeptide structure. Lyophilized powder stored at -20°C retains potency for 12–24 months. After reconstitution in bacteriostatic water, stability is approximately 4–6 weeks at 2–8°C. KPV dissolves rapidly — it typically requires less than 2 minutes of gentle agitation. Because the molecule is so small, standard HPLC purity assessment is especially important; small molecule impurities can constitute a larger proportion of the peptide mass than in larger peptides with more separated peaks.

What is KPV’s relationship to the Melanotan peptides?

What is KPV’s relationship to the Melanotan peptides?

Both KPV and the Melanotan peptides (MT-I, MT-II) act on melanocortin receptors. Melanotan I (afamelanotide) is a superpotent alpha-MSH analog with high MC1R affinity that produces strong pigmentation responses. MT-II is non-selective across MC1R through MC5R. KPV is the anti-inflammatory C-terminal fragment of alpha-MSH, which means it shares receptor family but with a functionally distinct emphasis — anti-inflammatory signaling rather than pigmentation or sexual arousal pathways. Researchers studying melanocortin receptor pharmacology use all three as distinct pharmacological tools to dissect receptor subtype contributions.

For research and laboratory use only. Not for human consumption. All peptides are sold strictly as research chemicals.